Relapse in IgG4-related disease: mechanisms, predictors, and prevention
- 1Department of Rheumatology and Immunology, Peking University Third Hospital
- 2Beijing Key Laboratory of Clinical Evaluation of Cardiovascular-Kidney-Metabolic and Immuno-Inflammatory Innovative Drugs and Medical Devices, Peking University Third Hospital
Abstract
Immunoglobulin G4-related disease (IgG4-RD) is a chronic fibroinflammatory disorder with a high rate of disease relapse, contributing to fibrosis, organ damage, and cumulative treatment burden. Relapse in IgG4-RD can occur either in previously affected organs or as de novo organ involvement. Recent advances have shown that both innate and adaptive immune responses contribute to disease persistence and relapse. Regarding risk factors, multiple clinical and serological characteristics as well as treatment-related factors have been associated with disease relapse. Therapeutic strategies have consequently evolved from remission induction alone toward relapse prevention and long-term disease control. Maintenance glucocorticoids, conventional immunosuppressive agents, rituximab, and emerging targeted therapies have demonstrated varying degrees of efficacy in reducing recurrence. In this review, we summarize current evidence regarding relapse patterns, underlying mechanisms, risk factors, and therapeutic approaches in IgG4-RD, with the aim of improving relapse prediction and guiding personalized long-term management.
Related
- Inflammatory memory as a potential driver of rosacea pathogenesis: integrating mechanisms of chronic relapse and perspectives on disease modification
- High-altitude gastric disorders: insights into maladaptation pathophysiological mechanisms, disease spectrum and prevention strategies
- Clinical and radiologic predictors of one-year surgical outcomes in Crohn’s disease–related intra-abdominal abscesses
- Traditional Chinese medicine-related interventions and the cGAS–STING axis in neuroinflammation: disease contexts and mechanisms of action
- Health-related quality of life deterioration in pediatric MOGAD patients: role of age at onset, phenotype and relapse pattern
BibTeX
@article{ge2026relapse,
title = {{Relapse in IgG4-related disease: mechanisms, predictors, and prevention}},
author = {Junyi Ge and Jingyi Xu and Jinxia Zhao},
journal = {Frontiers in Immunology},
year = {2026},
month = nov,
doi = {10.3389/fimmu.2026.1939768},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1939768/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Relapse in IgG4-related disease: mechanisms, predictors, and prevention
AU - Junyi Ge
AU - Jingyi Xu
AU - Jinxia Zhao
PY - 2026
DA - 2026/11/16
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1939768
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1939768/full
AB - Immunoglobulin G4-related disease (IgG4-RD) is a chronic fibroinflammatory disorder with a high rate of disease relapse, contributing to fibrosis, organ damage, and cumulative treatment burden. Relapse in IgG4-RD can occur either in previously affected organs or as de novo organ involvement. Recent advances have shown that both innate and adaptive immune responses contribute to disease persistence and relapse. Regarding risk factors, multiple clinical and serological characteristics as well as treatment-related factors have been associated with disease relapse. Therapeutic strategies have consequently evolved from remission induction alone toward relapse prevention and long-term disease control. Maintenance glucocorticoids, conventional immunosuppressive agents, rituximab, and emerging targeted therapies have demonstrated varying degrees of efficacy in reducing recurrence. In this review, we summarize current evidence regarding relapse patterns, underlying mechanisms, risk factors, and therapeutic approaches in IgG4-RD, with the aim of improving relapse prediction and guiding personalized long-term management.
SN - 1664-3224
ER -